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Sub-Saharan Africa has generally experienced few cases and deaths of coronavirus
disease 2019 (COVID-19). In addition to other potential explanations for the few cases
and deaths of COVID-19 such as the population socio-demographics, early lockdown
measures and the possibility of under reporting, we hypothesize in this mini review that
individuals with a recent history of malaria infection may be protected against infection
or severe form of COVID-19. Given that both the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and Plasmodium falciparum (P. falciparum) merozoites bind
to the cluster of differentiation 147 (CD147) immunoglobulin, we hypothesize that the
immunological memory against P. falciparum merozoites primes SARS-CoV-2 infected
cells for early phagocytosis, hence protecting individuals with a recent P. falciparum
infection against COVID-19 infection or severity. This mini review therefore discusses
the potential biological link between P. falciparum infection and COVID-19 infection or
severity and further highlights the importance of CD147 immunoglobulin as an entry point
for both SARS-CoV-2 and P. falciparum into host cells.
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INTRODUCTION
The corona virus disease 2019 (COVID-19) pandemic continues to spread and ravage the
world with more than 79,673,754 confirmed cases including 1,761,381 confirmed deaths as of
28th December, 2020 (1). COVID-19 is caused by a novel coronavirus known as the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronaviruses belong to a family of
enveloped single-stranded +sense RNA viruses, ranging from 16 to 32 kb in length and can be
divided into four major genera (2). The novel SARS-CoV-2 was named so after being reported
to be phylogenetically close to the coronavirus that cause severe acute respiratory syndrome
(SARS-CoV) (3).
Several studies have been undertaken in search for an effective treatment for COVID-19. A
recent review and meta-analysis of 7 randomized clinical trials and 14 cohort studies (20,979
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patients) has reported a lack of efficacy for hydroxychloroquine
in reducing short-term mortality in hospitalized COVID-19
patients or in reducing the risk of hospitalization in COVID-
19 outpatients (4). Randomized controlled trials have recently
reported effective treatment against COVID-19. Dexamethasone
has been reported to reducemortality among COVID-19 patients
on respiratory support (5) while remdesivir has been reported
to reduce both mortality and recovery time among hospitalized
adults with COVID-19 pneumonia (6). A total of seven vaccines
have also received emergency use authorization/approval to-
date in some countries (7) while many more vaccines remain
in development. Among these, BNT162b2 (also known as the
Pfizer–BioNTech COVID-19 vaccine) has been authorized for
emergency use in the United Kingdom, mRNA-1273 (also known
as the Moderna COVID-9 vaccine) received emergency use
authorization in the United States and Canada, CoronaVac has
received emergency authorization for use in China, Sputnik V
has been authorized for use among individuals aged 60 years
and above in Russia, BBIBP-CorV has received authorization
for use in Bahrain, China and the United Arab Emirates while
EpiVacCorona is set to be rolled out in Russia. The Oxford-
AstraZeneca coronavirus vaccine is the latest to receive approval
for use in the United Kingdom as of 30th December, 2020.
However, efficacy and long term safety of these vaccines needs
to be carefully monitored.
Globally, Africa stands out as the region least affected by
the COVID-19 epidemic, with 63,344 reported deaths and
2,239,023 recoveries out of the 2,677,672 reported cases as of
29th December, 2020 (8). The Central, Western and Eastern parts
of Africa harbor the greatest burden of malaria as compared
with the Northern and Southern parts of Africa. Interestingly,
within Africa, the Central, Western and Eastern parts of Africa
further stand out to be least affected regions (1,463 reported
deaths and 67,026 recoveries out of 73,317 reported cases; 3,187
reported deaths and 214,701 recoveries out of 239,216 reported
cases; and 5,917 reported deaths and 250,296 recoveries out
of 319,156 reported cases, respectively), as compared to the
Northern (23,766 reported deaths and 757,828 recoveries out of
911,486 reported cases) and Southern (29,011 reported deaths
and 949,172 recoveries out of 1,134,497 reported cases) parts of
Africa as of 29th December, 2020 (8). Although factors such as
extent of testing and patient demographics may be responsible
for the observed regional differences in the effect of the COVID-
19 pandemic, the Central, Western and Eastern parts of Africa
conspicuously stand out as regions most affected by malaria
globally. However, it is worthy of note that the trajectory of
COVID-19 pandemic in sub-Saharan Africa is not well-known
due to a paucity of seroprevalence data. A study by Uyoga
et al. (9) has reported a SARS-CoV-2 seroprevalence of 5.63
(4.83–6.49) among Kenyan blood donors while a SARS-CoV-2
seroprevalence of 12.3 (9.0–15.7) has been reported among health
care workers in Malawi (10). These seroprevalences are higher
than the global pooled seroprevalence of 3.38 (3.05–3.72) that
Abbreviations: CD, cluster of differentiation; COVID-19, coronavirus disease
2019; G6PD, glucose-6-phosphate dehydrogenase; PICALM, phosphatidylinositol
binding clathrin assembly protein; SARS-CoV-2, Novel coronavirus.
has been reported by a systematic review and meta-analysis (11),
suggesting that there are possibly many more infections that are
possibly asymptomatic or mild in nature.
Africa is the continent with the highest burden of malaria
globally accounting for 93% of global malaria cases and 94% of
malaria deaths (12). It is worthy of note that more than half
of global malaria cases in 2018 were attributed to 6 African
countries, that is Nigeria (25%), the Democratic Republic of the
Congo (12%), Uganda (5%), and Côte d’Ivoire, Mozambique
and Niger (4% each) (12). We hypothesize that the low effects
of COVID-19 observed mainly in sub-Saharan Africa is due
to interplay between active or a recent history of Plasmodium
falciparum (P. falciparum) infection with COVID-19 disease
acquisition or progression. We discuss below the association
between P. falciparum infection and COVID-19 infection or
severity. We further discuss the importance of CD147 as an entry
route for both SARS-CoV-2 and P. falciparum into host cells.
DISCUSSION
Plasmodium falciparum and SARS-CoV-2
Co-infection
As of 29th December, 2020, With 2,677,672 confirmed cases
and 63,344 confirmed deaths (8), Africa remains the least hit
continent by the COVID-19 pandemic sharing only around 3.4
and 3.6% confirmed cases and deaths, respectively, of the world’s
79,673,754 confirmed cases and 1,761,381 confirmed deaths (1)
as of 29th December, 2020. Increasing malaria incident rates
have been reported to be associated with decreased COVID-19
incident rates (13, 14). It has been hypothesized that induction of
interferons and neutralizing antibodies due to chronic infection
by P. falciparum may contribute to natural immunity against
SARS-CoV-2 in P. falciparum endemic areas (15).
Chloroquine/hydroxychloroquine pre-exposure prophylaxis
has been suggested as the reason behind the low incidences
of COVID-19 in malaria endemic countries (16). However, it
should be noted that chloroquine/hydroxychloroquine are no
longer first line drugs for treatment of P. falciparum malaria
and the World Health Organization recommends artemisinin-
based combination therapies for the treatment of uncomplicated
P. falciparum malaria (17) highlighting that other factors
such as population socio-demographics, immunological factors
and genetic susceptibility could be at play. For example,
previous exposure of children to coronavirus OC43 could be
protective against severe COVID-19 through cross-immunity
since SARS-CoV-2 is closely related to coronavirus OC43 (18).
An epidemiological study in a P. falciparum endemic area in
India has also reported a negative correlation between 10-year
annual parasite index scores and the number of COVID-19
cases (19).
The immunoglobulin CD147 has been reported to form a
complex with CD98 (CD147-CD98 protein complex) that is
involved in the attachment and entry of viruses like Chikungunya
into human cells (20), highlighting its importance in viral
infection of host cells. Elevated plasma levels of CD147 have been
reported among patients with diabetes as compared to healthy
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controls and predicted mortality over a 10-year period among
the diabetic patients (21). The elevated plasma levels of CD147
among patients with diabetes may be due to overexpression
of CD147 as a transmembrane glycoprotein. Overexpression of
CD147 on host cells may facilitate more viral entry into host
cells and may partly explain the high mortality of COVID-
19 that has been reported among patients with diabetes. The
CD147 has been reported to facilitate entry of SARS-CoV-
2 and P. falciparum into host cells (22, 23). We therefore
hypothesize that the immunological memory elicited following
binding of P. falciparum to CD147 is protective against SARS-
CoV-2 infection or severe COVID-19. We highlight below the
probablemechanisms through which P. falciparum infectionmay
be protective against SARS-CoV-2 infection or severe COVID-
19. We further highlight the importance of CD147 as an entry
point for SARS-CoV-2 into host cells.
Glucose-6-phosphate dehydrogenase (G6PD) has also been
suggested to play a role in COVID-19 infection and severity
(24) and has also been associated with infection of cells with
human coronaviruses (25). However, inherited deficiency of
erythrocytes G6PD has been reported to confer protection
against severe P. falciparum malaria (26). It has also been
hypothesized that protection against severe malaria is through
early phagocytosis of G6PD-deficient erythrocytes that are
parasitized by P. falciparum. We hypothesize that a recent
P. falciparum infection may offer the host an immunological
memory that marks a SARS-CoV-2-CD147 infected cell for early
phagocytosis. Interestingly, reports from the United Kingdom
and the United States indicate increased rates of COVID-
19 infection and mortality among Blacks and Asians. The
increased vulnerability to COVID-19 infection among Blacks
in the United Kingdom and the United States may thus be
attributed to inherited G6PD deficiency and subsequent lack of
the protective effect of P. falciparum infection history. However,
the increased vulnerability could be due to socio-economic
conditions, inability to be socially distanced and higher rates of
hypertension and obesity that have been reported most especially
among Blacks in the United States.
A study by Iesa et al. (27) has conducted a search of B-
and T-cell immunodominant epitope as well as B- and T-cell
major histocompatibility complex (MHC) restricted epitopes
for shared sequences between P. falciparum and SARS-CoV-
2. They reported no significantly shared homology between
P. falciparum B-cell epitopes with SARS-CoV-2, suggesting
that no antibodies to P. falciparum could be proposed as
eliciting an immune response against infection with SARS-CoV-2
through cross-reactivity. However, Iesa et al. (27) observed more
than 40% of identities between SARS-CoV-2 N-protein (amino
acids 215–227) and P. falciparum thrombospondin-related
anonymous protein (TRAP) epitopes located at amino acids
509–523 and also between SARS-CoV-2 open reading frame 1ab
(ORF1ab) and TRAP (amino acids 101–130). The immunological
memory elicited following P. falciparum infection could be
protective against SARS-CoV-2 infection or severe COVID-
19 through the original antigenic sin theory (28), where a
second antigen relies on the memory established by the first
antigen to initiate response. Iesa et al.’s study has revealed
several conserved tetrapeptides and pentapeptides between P.
falciparum and SARS-CoV-2 in the T-cell immunodominant
epitope and T-cell MHC restricted epitopes. Both epitopes
have been reported to stimulate CD8+ T-lymphocyte response
through the HLA-A.02:01 recognition and it has been suggested
that the memory of the cellular adaptive immunity mounted
against the TRAP-immunodominant epitope could recognize
the 219-LALLLLDRL-227–HLA-A∗02:01 complexes originating
from SARS-CoV-2 infection in malaria-endemic regions and
trigger an immune response (27). Much as these hypotheses
need to be tested, we acknowledge that the protective effect of
P. falciparum against COVID-19 infection/severity may be due
to other biochemical or immunological processes that need to
be elucidated.
It is also worthy of note that many areas of Africa such as
Rwanda, Central and North Eastern Kenya and vast areas of
Ethiopia have quite low malaria incidences, yet they do not seem
to be more highly impacted by COVID-19. If P. falciparum
infection is indeed protective against SARS-CoV-2 infection or
severe form of COVID-19, protection in such areas with low P.
falciparum infection could be due to a long lived immunological
memory. For example, antibodies against P. falciparum have been
reported to persist with a half-life of 5–10 years (29, 30).
Role of CD147 Receptor in Plasmodium
falciparum and SARS-CoV-2 Infection
The primary route of infection by SARS-CoV-2 is facilitated by
its ability to attach to host cell receptor where they (SARS-CoV-
2) enter host cells through various mechanisms. SARS-CoV-2 has
been reported to infect host cells through interaction of its spike
(S) protein with angiotensin-converting enzyme 2 (ACE2), in a
process that is primed by the trans-membrane serine protease
2 (31–35). Entry through endocytosis has also been described
facilitated by the S-protein, whose S1 sub unit facilitates receptor
binding while the S2 subunit facilitates membrane fusion (36).
Endocytosis occurs through clathrin-coated pits, where there
is abundance of phosphatidylinositol binding clathrin assembly
protein (PICALM) (37).
The CD147 (also known as basigin) has also been reported
as an entry route for SARS-CoV-2 into host cells (22,
38, 39) although a study by Shilts and Wright (40) has
reported no evidence for CD147 as a direct SARS-CoV-2 spike
binding receptor. The CD147 belongs to the immunoglobulin
superfamily and has been reported to be a highly glycosylated
trans-membrane protein (41, 42). The CD147 protein is
present in many cell types, including leukocytes, endothelial
haematopoietic and epithelial, endothelial cells where they are
expressed at varying expression levels (43, 44). The CD147 has
been reported to support platelet–monocyte interactions and also
to promote monocyte recruitment to the arterial wall (45). The
CD147 has been described to present as a possible novel target
to counter vascular inflammation and atherosclerotic lesion
development (45).
The CD147 receptor is among a plethora of molecules that
play essential roles in invasion of erythrocytes by P. falciparum
(46). Both CD147 and Cyclophilin B have been reported to
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bind to merozoites simultaneously, thereby indicating that these
proteins bind to independent ligands on the merozoite surface
that are, most likely, P. falciparum Reticulocyte Binding Protein
Homolog 5 (PfRh5) and P. falciparum rhoptry-associated protein
complex 3 (PfRhopH3) respectively, (47). Inhibition of CD147
through anti-CD147 antibodies has also been reported to block
parasite invasion (23). Crosnier and colleagues reported that
MEM-M6/6 antibody almost completely blocked the invasion of
the parasite at the concentration of 10 µg/ml (23).
CONCLUSION
There is enough evidence for both low infection rates and less
severe COVID-19 disease in P. falciparum endemic areas. The
biology underlying this observation needs to be elucidated in
order to understand the pathophysiology of COVID-19 disease.
The CD147 may as well-need attention as an entry route for both
SARS-CoV-2 and P. falciparum into host cells.
FUTURE STEPS
There is need for studies to investigate the role of P. falciparum
infection on the etiology of COVID-19. Studies that compare
outcomes in patients with a recent history of P. falciparum
infection with those in patients with no recent P. falciparum
infection coupled with studies that provide immune profiles
in patients infected with P. falciparum, SARS-CoV-2, and P.
falciparum-SARS-CoV-2 co-infection may provide a stepping
stone. More experimental studies are also required to investigate
the potential role of P. falciparum infection on SARS-CoV-2
infection or COVID-19 severity.
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